Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Prostate Cancer Research Today


View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications

Volume 1 (2004), Issue 5 (December)

  1. Noninvasive in vivo whole body luminescent analysis of luciferase labelled orthotopic prostate tumours.
    Eur J Cancer, 40(18): 2851-8. [Abstract] [Full-text]
  2. Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.
    Eur J Cancer, 40(18): 2837-44. [Abstract] [Full-text]
  3. AMP-activated protein kinase activity is required for vanadate-induced hypoxia-inducible factor 1alpha expression in DU145 cells.
    Carcinogenesis, 25(12): 2497-507. [Abstract] [Full-text]
  4. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.
    Cancer Res, 64(23): 8715-22. [Abstract] [Full-text]
  5. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.
    Cancer Res, 64(23): 8620-9. [Abstract] [Full-text]
  6. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression.
    Cancer Res, 64(23): 8526-33. [Abstract] [Full-text]
  7. Laparoscopic radical prostatectomy: early safety and efficacy.
    ANZ J Surg, 74(12): 1065-8. [Abstract] [Full-text]
  8. Prostate cancer incidence and survival in relation to education (United States).
    Cancer Causes Control, 15(9): 939-45. [Abstract] [Full-text]
  9. A prospective study of diet and prostate cancer in Japanese men.
    Cancer Causes Control, 15(9): 911-20. [Abstract] [Full-text]
  10. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression.
    Oncogene, 23(56): 9034-41. [Abstract] [Full-text]
  11. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.
    Oncogene, 23(56): 9111-9. [Abstract] [Full-text]
  12. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study.
    Am J Hum Genet, 76(1): 82-90. [Abstract] [Full-text]
  13. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
    Steroids, 69(13): 795-801. [Abstract] [Full-text]
  14. Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy?
    Eur Urol, 47(1): 45-50; discussion 50-1. [Abstract] [Full-text]
  15. Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A Multiinstitutional Prospective European Study.
    Eur Urol, 47(1): 38-44; discussion 44. [Abstract] [Full-text]
  16. Non-invasive detection of prostate cancer by electromagnetic interaction.
    Eur Urol, 47(1): 29-37; discussion 37. [Abstract] [Full-text]
  17. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
    Eur Urol, 47(1): 16-21. [Abstract] [Full-text]
  18. Expression patterns of potential therapeutic targets in prostate cancer.
    Int J Cancer, 113(4): 619-28. [Abstract] [Full-text]
  19. EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2.
    Int J Cancer, 113(4): 561-7. [Abstract] [Full-text]
  20. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells.
    Int J Cancer, 113(4): 660-9. [Abstract] [Full-text]
  21. Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack.
    Prostate, 62(2): 105-14. [Abstract] [Full-text]
  22. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
    Prostate, 62(2): 148-64. [Abstract] [Full-text]
  23. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer.
    Prostate, 62(2): 140-7. [Abstract] [Full-text]
  24. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo.
    Prostate, 62(2): 165-86. [Abstract] [Full-text]
  25. Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action.
    Prostate, 62(2): 133-9. [Abstract] [Full-text]
  26. Access of tumor-derived macromolecules and cells to the blood: an electron microscopical study of structural barriers in microvessel clusters in highly malignant primary prostate carcinomas.
    Prostate, 62(2): 123-32. [Abstract] [Full-text]
  27. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer.
    Prostate, 62(2): 115-22. [Abstract] [Full-text]
  28. Increased Nox1 and hydrogen peroxide in prostate cancer.
    Prostate, 62(2): 200-7. [Abstract] [Full-text]
  29. Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines.
    Prostate, 62(2): 187-99. [Abstract] [Full-text]
  30. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.
    Clin Cancer Res, 10(23): 8037-47. [Abstract] [Full-text]
  31. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
    Clin Cancer Res, 10(23): 8018-27. [Abstract] [Full-text]
  32. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses.
    Clin Cancer Res, 10(23): 7994-8004. [Abstract] [Full-text]
  33. Immune-based therapies for prostate cancer.
    Immunol Lett, 96(1): 3-9. [Abstract] [Full-text]
  34. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis.
    Proc Natl Acad Sci U S A, 101(49): 17204-9. [Abstract] [Full-text]
  35. Prostate cancer and sexuality: implications for nursing.
    Geriatr Nurs, 25(6): 341-7. [Abstract] [Full-text]
  36. Barriers to planning and conducting a screening: prostate cancer.
    Geriatr Nurs, 25(6): 336-40. [Abstract] [Full-text]
  37. Unwanted control: how patients in the primary care setting decide about screening for prostate cancer.
    Patient Educ Couns, 56(1): 116-24. [Abstract] [Full-text]
  38. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
    Int J Radiat Oncol Biol Phys, 60(5): 1631-8. [Abstract] [Full-text]
  39. Magnetic resonance assessment of prostate localization variability in intensity-modulated radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 60(5): 1611-21. [Abstract] [Full-text]
  40. Online image-guided intensity-modulated radiotherapy for prostate cancer: How much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery.
    Int J Radiat Oncol Biol Phys, 60(5): 1602-10. [Abstract] [Full-text]
  41. MR and CT image fusion for postimplant analysis in permanent prostate seed implants.
    Int J Radiat Oncol Biol Phys, 60(5): 1572-9. [Abstract] [Full-text]
  42. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer.
    Int J Radiat Oncol Biol Phys, 60(5): 1373-8. [Abstract] [Full-text]
  43. Impact of knee support and shape of tabletop on rectum and prostate position.
    Int J Radiat Oncol Biol Phys, 60(5): 1364-72. [Abstract] [Full-text]
  44. A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.
    Int J Radiat Oncol Biol Phys, 60(5): 1347-50. [Abstract] [Full-text]
  45. Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing.
    Free Radic Biol Med, 38(1): 50-7. [Abstract] [Full-text]
  46. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome?
    Cancer Genet Cytogenet, 156(1): 31-6. [Abstract] [Full-text]
  47. Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.
    Mol Cancer, 3: 31. [Abstract] [Full-text]
  48. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis.
    Cancer, 101(12): 2755-9. [Abstract] [Full-text]
  49. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
    Cancer, 101(12): 2881-91. [Abstract] [Full-text]
  50. Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma.
    Cancer, 101(12): 2744-54. [Abstract] [Full-text]
  51. Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies.
    Clin Sci (Lond), 108(1): 1-11. [Abstract] [Full-text]
  52. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
    Urology, 64(6): 1238-43. [Abstract] [Full-text]
  53. Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model.
    Urology, 64(6): 1233-7. [Abstract] [Full-text]
  54. Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.
    Urology, 64(6): 1231.e1-3. [Abstract] [Full-text]
  55. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.
    Urology, 64(6): 1182-6. [Abstract] [Full-text]
  56. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial.
    Urology, 64(6): 1177-81. [Abstract] [Full-text]
  57. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999.
    Urology, 64(6): 1171-6. [Abstract] [Full-text]
  58. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy.
    Urology, 64(6): 1165-70. [Abstract] [Full-text]
  59. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
    Urology, 64(6): 1160-4. [Abstract] [Full-text]
  60. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study.
    Int J Cancer, 113(5): 819-24. [Abstract] [Full-text]
  61. Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers.
    Int J Cancer, 113(5): 811-8. [Abstract] [Full-text]
  62. Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study.
    Int J Cancer, 113(5): 835-40. [Abstract] [Full-text]
  63. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
    J Clin Invest, 114(12): 1774-81. [Abstract] [Full-text]
  64. Macronutrients, fatty acids, cholesterol and prostate cancer risk.
    Ann Oncol, 16(1): 152-7. [Abstract] [Full-text]
  65. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF).
    Cytokine, 29(2): 56-66. [Abstract] [Full-text]
  66. Autopsy case of prostate cancer with multiple endocrine neoplasia 2A.
    Pathol Int, 54(12): 918-23. [Abstract] [Full-text]
  67. Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus.
    Hum Genet, 116(1): 43-50. [Abstract] [Full-text]
  68. Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases.
    Support Care Cancer, 12(12): 882-4. [Abstract] [Full-text]
  69. Three-dimensional conformal radiotherapy in the treatment of prostate cancer in Australia and New Zealand: Report on a survey of radiotherapy centres and the proceedings of a consensus workshop.
    Australas Radiol, 48(4): 502-8. [Abstract] [Full-text]
  70. Australian and New Zealand three-dimensional conformal radiation therapy consensus guidelines for prostate cancer.
    Australas Radiol, 48(4): 493-501. [Abstract] [Full-text]
  71. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells.
    Oncogene, 23(58): 9326-35. [Abstract] [Full-text]
  72. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer.
    Cancer Gene Ther, 12(1): 90-100. [Abstract] [Full-text]
  73. A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer.
    Endocrinology, 146(1): 13-8. [Abstract] [Full-text]
  74. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.
    Cancer Res, 64(24): 9209-16. [Abstract] [Full-text]
  75. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling.
    Cancer Res, 64(24): 9185-92. [Abstract] [Full-text]
  76. HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
    Cancer Res, 64(24): 9144-51. [Abstract] [Full-text]
  77. Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5'-monophosphate dehydrogenase.
    Cancer Res, 64(24): 9049-56. [Abstract] [Full-text]
  78. Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus.
    Cancer Res, 64(24): 8906-10. [Abstract] [Full-text]
  79. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells.
    Cancer Res, 64(24): 8867-75. [Abstract] [Full-text]
  80. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells.
    Cancer Res, 64(24): 8860-6. [Abstract] [Full-text]
  81. Polycyclic aromatic hydrocarbon-DNA adducts in prostate cancer.
    Cancer Res, 64(24): 8854-9. [Abstract] [Full-text]
  82. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion.
    Cancer Res, 64(24): 8826-30. [Abstract] [Full-text]
  83. Amiloride potentiates TRAIL-induced tumor cell apoptosis by intracellular acidification-dependent Akt inactivation.
    Biochem Biophys Res Commun, 326(4): 752-8. [Abstract] [Full-text]
  84. Frequent loss of estrogen and progesterone receptors in human prostatic tumors determined by quantitative real-time PCR.
    Mol Cell Endocrinol, 229(1): 103-10. [Abstract] [Full-text]
  85. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns.
    Clin Biochem, 38(1): 58-65. [Abstract] [Full-text]
  86. Improving overall men's health and potentially reducing the risk of certain cancers via serum markers and risk assessment for coronary heart disease.
    Urol Oncol, 22(6): 485-9. [Abstract] [Full-text]
  87. The association between obesity and the progression of prostate and renal cell carcinoma.
    Urol Oncol, 22(6): 478-84. [Abstract] [Full-text]
  88. Cisplatin inhibits the expression of X-linked inhibitor of apoptosis protein in human LNCaP cells.
    Urol Oncol, 22(6): 453-60. [Abstract] [Full-text]
  89. Psychometric evaluation of the Cognitive Appraisal of Health Scale with patients with prostate cancer.
    J Adv Nurs, 49(1): 78-86. [Abstract] [Full-text]
  90. Hyperbaric oxygen does not accelerate latent in vivo prostate cancer: implications for the treatment of radiation-induced haemorrhagic cystitis.
    BJU Int, 94(9): 1275-8. [Abstract] [Full-text]
  91. Variation in patterns of practice in diagnosing screen-detected prostate cancer.
    BJU Int, 94(9): 1239-44. [Abstract] [Full-text]
  92. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.
    BJU Int, 94(9): 1235-8. [Abstract] [Full-text]
  93. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
    Clin Chem, 51(1): 102-12. [Abstract] [Full-text]
  94. gamma-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis.
    Proc Natl Acad Sci U S A, 101(51): 17825-30. [Abstract] [Full-text]
  95. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients.
    Prostate, 62(3): 233-42. [Abstract] [Full-text]
  96. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy.
    Prostate, 62(3): 224-32. [Abstract] [Full-text]
  97. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
    Prostate, 62(3): 217-23. [Abstract] [Full-text]
  98. Stable expression of C/EBPalpha in prostate cancer cells down-regulates metallothionein and increases zinc-induced toxicity.
    Prostate, 62(3): 209-16. [Abstract] [Full-text]
  99. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
    Prostate, 62(3): 299-306. [Abstract] [Full-text]
  100. Ability of PSA-positive circulating macrophages to detect prostate cancer.
    Prostate, 62(3): 290-8. [Abstract] [Full-text]
  101. Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo.
    Prostate, 62(3): 282-9. [Abstract] [Full-text]
  102. Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP.
    Prostate, 62(3): 275-81. [Abstract] [Full-text]
  103. Loss of heterozygosity in chromosomal region 16q24.3 associated with progression of prostate cancer.
    Prostate, 62(3): 267-74. [Abstract] [Full-text]
  104. Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro.
    Prostate, 62(3): 253-9. [Abstract] [Full-text]
  105. Explaining racial differences in prostate cancer in the United States: sociology or biology?
    Prostate, 62(3): 243-52. [Abstract] [Full-text]
  106. Post-laminectomy long-term survival of a patient with spinal cord compression secondary to metastatic prostate cancer.
    Int J Clin Oncol, 9(6): 520-2. [Abstract] [Full-text]
  107. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
    J Med Chem, 47(27): 6716-29. [Abstract] [Full-text]
  108. Basal cell adenoma of prostate.
    Urol Res, 32(6): 421-2. [Abstract] [Full-text]
  109. Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells.
    Urol Res, 32(6): 406-10. [Abstract] [Full-text]
  110. Myosin regulation in the migration of tumor cells and leukocytes within a three-dimensional collagen matrix.
    Cell Mol Life Sci, 62(1): 65-76. [Abstract] [Full-text]
  111. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies.
    Eur J Cancer, 41(1): 61-70. [Abstract] [Full-text]
  112. Malignant melanoma with gall bladder metastasis as a second neoplasm in the course of prostate cancer.
    Pathol Oncol Res, 10(4): 243-5. [Abstract] [Full-text]
  113. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma.
    Cancer, 103(1): 11-21. [Abstract] [Full-text]
  114. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
    Cancer, 103(1): 76-84. [Abstract] [Full-text]
  115. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.
    Int J Cancer, 113(6): 870-80. [Abstract] [Full-text]
  116. Do dietary lycopene and other carotenoids protect against prostate cancer?
    Int J Cancer, 113(6): 1010-4. [Abstract] [Full-text]
  117. Birth size and subsequent risk for prostate cancer: a prospective population-based study in Norway.
    Int J Cancer, 113(6): 1002-4. [Abstract] [Full-text]
  118. Expression and functional role of CCR9 in prostate cancer cell migration and invasion.
    Clin Cancer Res, 10(24): 8743-50. [Abstract] [Full-text]
  119. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
    Clin Cancer Res, 10(24): 8728-34. [Abstract] [Full-text]
  120. A quantitative promoter methylation profile of prostate cancer.
    Clin Cancer Res, 10(24): 8472-8. [Abstract] [Full-text]
  121. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer.
    Clin Cancer Res, 10(24): 8460-4. [Abstract] [Full-text]
  122. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer.
    Clin Cancer Res, 10(24): 8351-6. [Abstract] [Full-text]
  123. Differential effects of delivery of omega-3 fatty acids to human cancer cells by low-density lipoproteins versus albumin.
    Clin Cancer Res, 10(24): 8275-83. [Abstract] [Full-text]
  124. Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.
    Clin Cancer Res, 10(24): 8147-51. [Abstract] [Full-text]
  125. Mitochondrial DNA haplotyping revealed the presence of mixed up benign and neoplastic tissue sections from two individuals on the same prostatic biopsy slide.
    J Clin Pathol, 58(1): 83-6. [Abstract] [Full-text]
  126. Expression of prostate specific antigen in male breast cancer.
    J Clin Pathol, 58(1): 69-71. [Abstract] [Full-text]
  127. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer.
    J Gene Med, 6(12): 1343-57. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.

Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)

Prostate Cancer Books

Beating Prostate Cancer (Hormonal Therapy & Diet, 1)

Beating Prostate Cancer (Hormonal Therapy & Diet, 1)